Major Corporate Developments: The application for a dual primary listing by Baidu Group-SW (09888) has been confirmed by the Hong Kong Stock Exchange. The company also proposed granting issuance authority and share repurchase authorization.
Ribo Biology-B (06938) announced positive Phase 2A study results for its core product, VORTOSIRAN, targeting CAD.
Pegasus Biopharmaceutical-B (02565) reported that the first nationwide commercial prescriptions for Paidakang® have been filled and the conditions for the second milestone payment have been met.
CSPC Pharmaceutical Group (01093) has officially initiated a Phase II clinical trial in China for SYS 6026 injection, intended for the treatment of HPV16 or 18-associated cervical high-grade squamous intraepithelial lesions.
Power MP Technology (08198) plans to establish a partnership, primarily engaged in providing platform-based computing power services in China.
IndigoStar (08373) intends to acquire a property in Singapore for SGD 16.588 million.
Operational and Financial Performance: NEWBORNTOWN (09911) expects its first-half revenue to increase by approximately 34.3% to 38.8% year-on-year, driven by growth in its AI-powered social and short-form drama businesses.
Ronshine China (03301) reported total contracted sales of approximately RMB 1.294 billion for the first half of the year, representing a year-on-year decrease of 38.6%.
Wang On Properties (01243) achieved contracted sales of approximately HKD 1.2121 billion for the three-month period ended June 30.
Unisound (09678) anticipates first-half revenue to be between RMB 530 million and RMB 580 million, a year-on-year increase of 31% to 43%.
MicroPort MedBot-B (02252) issued a positive profit alert, expecting an interim net profit of approximately RMB 28 million to RMB 40 million, turning a loss from the same period last year into a profit.
Comments